These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 29240962

  • 1. Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system.
    Triantafyllis AS, Bennett J, Pagourelias E, McCutcheon K, Adriaenssens T, Sinnaeve PR, Desmet W, Dubois C.
    Cardiol J; 2018; 25(4):470-478. PubMed ID: 29240962
    [Abstract] [Full Text] [Related]

  • 2. 5-Year clinical follow-up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents) study.
    Bennett J, Adriaenssens T, McCutcheon K, Dens J, Desmet W, Sinnaeve P, Vrolix M, Dubois C.
    Catheter Cardiovasc Interv; 2018 Nov 15; 92(6):E375-E380. PubMed ID: 29536609
    [Abstract] [Full Text] [Related]

  • 3. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study.
    Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo BK, Fitzgerald PJ, Mehran R, Lansky AJ.
    J Am Coll Cardiol; 2009 Mar 24; 53(12):1031-9. PubMed ID: 19298915
    [Abstract] [Full Text] [Related]

  • 4. Comparative Case-Control analysis of a dedicated self-expanding Biolimus A9-eluting Bifurcation stent versus provisional or mandatory side branch intervention strategies in the treatment of coronary bifurcation lesions.
    Ohlow MA, Farah A, Richter S, El-Garhy M, von Korn H, Lauer B.
    Catheter Cardiovasc Interv; 2017 Jul 24; 90(1):39-47. PubMed ID: 27651317
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K, Niemelä M, Romppanen H, Erglis A, Kumsars I, Maeng M, Holm NR, Lassen JF, Gunnes P, Stavnes S, Jensen JS, Galløe A, Narbute I, Sondore D, Christiansen EH, Ravkilde J, Steigen TK, Mannsverk J, Thayssen P, Hansen KN, Helqvist S, Vikman S, Wiseth R, Aarøe J, Jokelainen J, Thuesen L, Nordic PCI Study Group.
    JACC Cardiovasc Interv; 2013 Nov 24; 6(11):1160-5. PubMed ID: 24262616
    [Abstract] [Full Text] [Related]

  • 9. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug 24; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

  • 10. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
    Kern A, Gil RJ, Bojko K, Rzeszowski B, Bednarski K, Górny J, Bil J.
    Cardiol J; 2018 Aug 24; 25(2):188-195. PubMed ID: 28714525
    [Abstract] [Full Text] [Related]

  • 11. Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial.
    Ghione M, Wykrzykowska JJ, Windecker S, Serruys PW, Buszman P, Linke A, Sohn HY, Corti R, Antoni D, Wijns W, Estevez-Loureiro R, Morice MC, Van Es GA, van Geuns RJ, Juni P, Eerdmans P, De Vries T, Konik S, Di Mario C.
    Cardiol J; 2016 Aug 24; 23(6):626-636. PubMed ID: 27665852
    [Abstract] [Full Text] [Related]

  • 12. Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system.
    Verheye S, Buysschaert I, Grube E.
    EuroIntervention; 2015 Dec 24; 11(8):860-7. PubMed ID: 26696454
    [Abstract] [Full Text] [Related]

  • 13. The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations.
    Ferrarello S, Costopoulos C, Latib A, Naganuma T, Sticchi A, Figini F, Basavarajaiah S, Carlino M, Chieffo A, Montorfano M, Kawaguchi M, Naim C, Giannini F, Colombo A.
    J Invasive Cardiol; 2013 Sep 24; 25(9):436-40. PubMed ID: 23995715
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Outcomes of Different Two-Stent Techniques With Second-Generation Drug-Eluting Stents for Unprotected Left Main Bifurcation Disease: Insights From the FAILS-2 Study.
    Pavani M, Conrotto F, Cerrato E, D'Ascenzo F, Kawamoto H, Núñez-Gil IJ, Pennone M, Garbo R, Tomassini F, Colombo F, Scacciatella P, Varbella F, Chieffo A, Colombo A, Escaned J.
    J Invasive Cardiol; 2018 Aug 24; 30(8):276-281. PubMed ID: 30068784
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
    Jensen LO, Thayssen P, Christiansen EH, Maeng M, Ravkilde J, Hansen KN, Hansen HS, Krusell L, Kaltoft A, Tilsted HH, Berencsi K, Junker A, Lassen JF, SORT OUT IV Investigators.
    J Am Coll Cardiol; 2016 Feb 23; 67(7):751-62. PubMed ID: 26892409
    [Abstract] [Full Text] [Related]

  • 16. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
    Jinnouchi H, Kuramitsu S, Shinozaki T, Hiromasa T, Kobayashi Y, Morinaga T, Yamaji K, Soga Y, Shirai S, Ando K.
    Catheter Cardiovasc Interv; 2016 Nov 23; 88(5):E132-E138. PubMed ID: 26708085
    [Abstract] [Full Text] [Related]

  • 17. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.
    JACC Cardiovasc Interv; 2013 Dec 23; 6(12):1263-6. PubMed ID: 24239202
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.
    Džavík V, Kaul U, Guagliumi G, Chevalier B, Smits PC, Stuteville M, Li D, Sudhir K, Grube E.
    Catheter Cardiovasc Interv; 2013 Sep 01; 82(3):E163-72. PubMed ID: 23225766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.